Portfolio growth was sustained in an uncertain environment of changing program priorities. Nonetheless, this past year's accomplishments also attest to the impressive competitive success of our University faculty. In the non-governmental area, support from Corporate sources and the Foundation and Association sectors continue to show steady increases. FY 94 also marked the implementation of the Chancellor's new research reallocation policy based on actual reimbursements for indirect costs.
Special services performed by staff continue to grow.
For example, a November 1993 Army Medical Research and Development Command solicitation of proposals for breast cancer projects prompted an outpouring of submissions, with special requirements for exhaustive safety plan documentation, coordinated with the University's Office of Environmental Health and Safety. Intense administrative system reviews and procedural oversight by the National Cancer Institute necessitated major staff effort, overarching routine operations. On the award side, the number of corporate research agreements negotiated and accepted for the University exceeded 250. Projects involving pharmaceutical drug trials or biotechnology projects continue to comprise the largest share of negotiated agreements. Increasing staff effort is devoted to compliance activities.